Mesoblast Limited (NASDAQ:MESO - Get Free Report) shares gapped up prior to trading on Thursday . The stock had previously closed at $16.09, but opened at $16.86. Mesoblast shares last traded at $17.18, with a volume of 170,466 shares.
Wall Street Analyst Weigh In
Several brokerages recently issued reports on MESO. Jefferies Financial Group lowered shares of Mesoblast from a "buy" rating to a "hold" rating in a research note on Friday, July 18th. Cantor Fitzgerald raised shares of Mesoblast to a "strong-buy" rating in a report on Monday, March 31st. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating, two have given a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, Mesoblast presently has a consensus rating of "Moderate Buy" and an average target price of $18.00.
Read Our Latest Stock Report on Mesoblast
Mesoblast Stock Down 2.6%
The business has a 50-day moving average of $11.73 and a 200-day moving average of $13.41. The company has a debt-to-equity ratio of 0.22, a current ratio of 0.96 and a quick ratio of 0.63.
Institutional Trading of Mesoblast
Institutional investors have recently added to or reduced their stakes in the company. Vanguard Personalized Indexing Management LLC lifted its holdings in Mesoblast by 27.0% during the 2nd quarter. Vanguard Personalized Indexing Management LLC now owns 13,331 shares of the company's stock valued at $145,000 after buying an additional 2,832 shares in the last quarter. Lazari Capital Management Inc. raised its position in Mesoblast by 2.2% during the 2nd quarter. Lazari Capital Management Inc. now owns 46,471 shares of the company's stock valued at $506,000 after purchasing an additional 1,003 shares in the last quarter. Ballentine Partners LLC bought a new stake in Mesoblast during the 2nd quarter valued at $124,000. Goldman Sachs Group Inc. bought a new stake in Mesoblast during the 1st quarter valued at $3,209,000. Finally, Cubist Systematic Strategies LLC raised its holdings in shares of Mesoblast by 104.3% in the first quarter. Cubist Systematic Strategies LLC now owns 71,891 shares of the company's stock valued at $897,000 after acquiring an additional 36,700 shares in the last quarter. Institutional investors own 1.43% of the company's stock.
About Mesoblast
(
Get Free Report)
Mesoblast Limited engages in the development of regenerative medicine products in Australia, the United States, Singapore, and Switzerland. The company offers products in the areas of cardiovascular, spine orthopedic disorder, oncology, hematology, and immune-mediated and inflammatory diseases. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells.
See Also
Before you consider Mesoblast, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Mesoblast wasn't on the list.
While Mesoblast currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
MarketBeat All Access